Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Consolidated Net Income rose 14377.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 127569.02%. This contributed to the annual value of $8.5 million for FY2024, which is 27314.7% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Consolidated Net Income is $4.6 million, which was up 14377.0% from $3.6 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Consolidated Net Income high stood at $7.2 million for Q4 2024, and its period low was -$8.9 million during Q3 2021.
  • Moreover, its 5-year median value for Consolidated Net Income was -$1.4 million (2022), whereas its average is -$1.5 million.
  • As far as peak fluctuations go, Niagen Bioscience's Consolidated Net Income plummeted by 11010.68% in 2021, and later soared by 2416000.0% in 2025.
  • Over the past 5 years, Niagen Bioscience's Consolidated Net Income (Quarter) stood at -$5.3 million in 2021, then skyrocketed by 72.88% to -$1.4 million in 2022, then skyrocketed by 107.89% to $114000.0 in 2023, then skyrocketed by 6197.37% to $7.2 million in 2024, then crashed by 36.23% to $4.6 million in 2025.
  • Its Consolidated Net Income stands at $4.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $5.1 million for Q1 2025.